RVVTF and 31R Related Headlines

Go Back

Nov 21, 2025 12:07PM Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Sep 19, 2025 05:00PM Revive Therapeutics closes second tranche of private placement for $91,400

Sep 19, 2025 05:00PM Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Sep 5, 2025 07:51PM Revive Therapeutics extends private placement offering deadline

Sep 5, 2025 07:50PM Revive Therapeutics Announces Extension of Proposed Private Placement

Aug 11, 2025 07:28PM Revive Therapeutics closes $60,900 private placement first tranche

Aug 11, 2025 07:28PM Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

Jul 30, 2025 08:21PM Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

Jul 8, 2025 05:10PM Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

RVVTF and 31R Related Press Releases

Go Back

Nov 21, 2025 12:07PM Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Sep 19, 2025 05:00PM Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Sep 5, 2025 07:50PM Revive Therapeutics Announces Extension of Proposed Private Placement

Aug 11, 2025 07:28PM Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

Jul 30, 2025 08:21PM Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

Jul 8, 2025 05:10PM Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

RVVTF and 31R Related SEC Filings

Go Back